Levetiracetam Farmoz (Levetiracetam)

• Levetiracetam is an antiepileptic drug that reduces seizure activity by modulating synaptic neurotransmitter release.
• It is indicated for several seizure types across different epilepsy syndromes.
• Partial‑onset seizures: helps control focal seizures by decreasing the frequency and intensity of seizure episodes in patients with focal epilepsy.
• Generalized tonic‑clonic seizures: contributes to the prevention of bilateral convulsive seizures, reducing the risk of injury and status epilepticus in generalized epilepsy.
• Myoclonic seizures: diminishes sudden, brief muscle jerks, improving daily function and quality of life for patients experiencing myoclonic epilepsy.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing neuronal membranes and reducing excessive synaptic firing. By limiting the release of excitatory neurotransmitters, the drug lowers neuronal hyperexcitability, thereby preventing the initiation and propagation of epileptic seizures. The precise downstream pathways remain under investigation, but the overall effect is a decrease in synchronized neuronal discharge associated with seizure activity.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: a transient feeling of light‑headedness or unsteadiness that may affect balance.
• Fatigue: persistent tiredness or lack of energy that is not alleviated by normal rest.
• Somnolence: increased daytime sleepiness that can impair alertness and concentration.
• Headache: mild to moderate cranial pain that may vary in intensity and duration.

Serious or Rare Side Effects

• Severe skin reactions: rare but potentially life‑threatening conditions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis requiring immediate medical attention.
• Mood alterations: emergence of depression, anxiety, irritability, or suicidal thoughts, warranting prompt evaluation.
• Blood dyscrasias: uncommon occurrences of leukopenia, thrombocytopenia, or anemia that may necessitate laboratory monitoring.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function and adjust dose as recommended.
• Hepatic impairment: monitor liver enzymes and consider dose modification if needed.
• Psychiatric history: observe for mood changes, depression, or suicidal ideation.
• Concomitant CNS depressants: use with caution as additive sedation may occur.
• Pregnancy: discuss potential risks and benefits with the prescriber before use.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety profile.

Major Interactions (Avoid)

• Carbamazepine: induces hepatic enzymes, significantly lowering levetiracetam plasma concentrations.
• Phenobarbital: strong enzyme inducer that reduces levetiracetam levels and may diminish seizure control.
• Phenytoin: increases metabolism of levetiracetam, potentially leading to subtherapeutic exposure.
• Rifampin: potent enzyme inducer that can markedly decrease levetiracetam concentrations.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance central nervous system depression, increasing drowsiness and coordination impairment.
• Other antiepileptic drugs: combined use may require dose adjustments based on clinical response.
• Oral contraceptives: levetiracetam may reduce hormonal efficacy, necessitating alternative contraception methods.
• Cimetidine: may increase levetiracetam levels modestly, requiring monitoring.